Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 6/20 | 0.49 |
| ▸ | ADRA1A | P35348 | 3/20 | 0.49 |
| ▸ | MEN1 | O00255 | 3/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.44 |
| ▸ | ATM | Q13315 | 1/20 | 0.43 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | ACHE | P22303 | 1/20 | 0.38 |
| ▸ | SCN7A | Q01118 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | DRD4 | P21917 | 1/20 | 0.37 |
| ▸ | LTA4H | P09960 | 1/20 | 0.37 |
| ▸ | CCR3 | P51677 | 1/20 | 0.37 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4856165 | 0.82 | DRD2 (0.51) | DRD2ADRA1AMEN1KMT2AATM | |
| SCHEMBL4852804 | 0.81 | DRD2 (0.53) | DRD2ADRA1AMEN1KMT2AATM | |
| SCHEMBL4856693 | 0.79 | DRD2 (0.49) | DRD2ADRA1AMEN1KMT2AATM | |
| SCHEMBL4852792 | 0.77 | DRD2 (0.43) | DRD2ADRA1AMEN1KMT2AATM | |
| SCHEMBL4852736 | 0.76 | DRD2 (0.60) | DRD2ADRA1AACHELTA4H | |
| SCHEMBL4854957 | 0.75 | DRD2 (0.64) | DRD2ADRA1ADRD4LTA4H | |
| SCHEMBL4848389 | 0.75 | DRD2 (0.43) | DRD2ADRA1AMEN1KMT2AATM | |
| SCHEMBL4853485 | 0.75 | DRD2 (0.63) | DRD2ADRA1AALDH1A1DRD4LTA4H | |
| Hydrochloric Acid SCHEMBL4855743 | 0.75 | DRD2 (0.63) | DRD2ADRA1ADRD4LTA4H | |
| Hydrochloric Acid SCHEMBL4847772 | 0.74 | DRD2 (0.46) | DRD2ADRA1AMEN1KMT2AATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7446204-B2 | Amino substituted aryloxybenzylpiperidine derivatives | H. LUNDBECK A/S (DK) | 2008-11-04 | — | — | US | disclosed |
| EP-1804796-A2 | AMINO SUBSTITUTED ARYLOXYBENZYLPIPERIDINE DERIVATIVES | H.Lundbeck A/S (DK) | 2007-07-11 | — | — | EP | disclosed |
| WO-2006041636-A2 | AMINO SUBSTITUTED ARYLOXYBENZYLPIPERIDINE DERIVATIVES | H.LUNDBECK A/S (DK) | 2006-04-20 | — | — | WO | disclosed |
| US-20060079524-A1 | Amino substituted aryloxybenzylpiperidine derivatives | H. LUNDBECK A/S | 2006-04-13 | — | — | US | disclosed |
| US-20060079522-A1 | Amino substituted aryloxybenzylpiperidine derivatives | H. LUNDBECK A/S (DK) | 2006-04-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060079524-A1 | Amino substituted aryloxybenzylpiperidine derivatives | MCHR1, MCHR2, MC4R | DRD2 198/4885ADRA1A 34/4885MEN1 1234/4885 |
| US-20060079522-A1 | Amino substituted aryloxybenzylpiperidine derivatives | MCHR1, MCHR2, MC4R | DRD2 192/4885ADRA1A 38/4885MEN1 1144/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.